Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alnus incana subsp. rugosa pollen is an allergenic extract derived from the pollen of the speckled alder tree, a species native to North America. [2] It is a biologic product used for both the diagnosis of allergies (via skin testing) and for allergen immunotherapy to treat patients with confirmed allergies to this specific pollen. [11] The therapy works by administering controlled, gradually increasing doses of the allergen subcutaneously, which modulates the immune system over time to reduce allergic sensitivity and induce tolerance. [10, 11] The product is available as an injectable solution or suspension and is marketed by companies including ALK-Abello, Inc. and Center Laboratories. [3, 4] It is an FDA-registered product that requires careful dose titration based on individual patient sensitivity. [4, 15]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Alnus incana subsp. rugosa pollen.